Bayer AG (NASDAQ:BAYRY) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, October 2nd.
Several other analysts also recently commented on BAYRY. Zacks Investment Research raised shares of Bayer AG from a “hold” rating to a “buy” rating and set a $148.00 price objective for the company in a research report on Tuesday, September 19th. BNP Paribas raised shares of Bayer AG from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Finally, Berenberg Bank downgraded shares of Bayer AG from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $148.00.
Shares of Bayer AG (NASDAQ BAYRY) traded up 1.19% on Monday, reaching $34.96. 501,913 shares of the company were exchanged. Bayer AG has a 12 month low of $22.88 and a 12 month high of $35.15. The company’s 50-day moving average price is $33.32 and its 200 day moving average price is $32.04. The company has a market cap of $121.96 billion and a price-to-earnings ratio of 20.13.
Bayer AG (NASDAQ:BAYRY) last released its quarterly earnings results on Thursday, July 27th. The company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.12. The firm had revenue of $13.41 billion during the quarter, compared to analyst estimates of $14.45 billion. Bayer AG had a net margin of 10.90% and a return on equity of 13.03%. On average, equities research analysts expect that Bayer AG will post $2.22 EPS for the current year.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/14/bayer-ag-bayry-upgraded-at-valuengine.html.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.